Carsten Munk

Summary

Affiliation: Heinrich Heine University
Country: Germany

Publications

  1. M nk C, Willemsen A, Bravo I. An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol Biol. 2012;12:71 pubmed publisher
    ....
  2. Munk C, Jensen B, Zielonka J, Haussinger D, Kamp C. Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein. Viruses. 2012;4:3132-61 pubmed publisher
    ..Both experimental evidence and the substantiation of the underlying dynamics through coevolutionary models are presented as complementary views of a coevolutionary arms race. ..
  3. Bähr A, Singer A, Hain A, Vasudevan A, Schilling M, Reh J, et al. Interferon but not MxB inhibits foamy retroviruses. Virology. 2016;488:51-60 pubmed publisher
    ..IFN-β treated THP-1 and THP-1 KO MxB cells showed the same extend of restriction to FV. Together, the data demonstrate that IFN-β inhibits FV early in infection and that MxB is not a restriction factor of FV. ..
  4. Zhang Z, Gu Q, Jaguva Vasudevan A, Hain A, Kloke B, Hasheminasab S, et al. Determinants of FIV and HIV Vif sensitivity of feline APOBEC3 restriction factors. Retrovirology. 2016;13:46 pubmed publisher
    ..Only A3Z3 and A3Z2Z3 inhibit Vif-deficient FIV. Feline A3s also are restriction factors for HIV and Simian immunodeficiency viruses (SIV). Surprisingly, HIV-2/SIV Vifs can counteract feline A3Z2Z3...
  5. Jaguva Vasudevan A, Hofmann H, Willbold D, Haussinger D, Koenig B, Munk C. Enhancing the Catalytic Deamination Activity of APOBEC3C Is Insufficient to Inhibit Vif-Deficient HIV-1. J Mol Biol. 2017;429:1171-1191 pubmed publisher
    ..We conclude that the enhanced enzymatic activity of A3C is insufficient to restrict HIV-1, indicating an unknown escape mechanism of HIV-1. ..
  6. Jaguva Vasudevan A, Goering W, Haussinger D, Munk C. Detection of APOBEC3 Proteins and Catalytic Activity in Urothelial Carcinoma. Methods Mol Biol. 2018;1655:97-107 pubmed publisher
    ..Here we combine independent immunoblotting with an in vitro activity assay technique, to detect and categorize specific A3s expressed in urothelial bladder cancer and other cancer cells. ..
  7. Gu Q, Zhang Z, Gertzen C, Haussinger D, Gohlke H, Munk C. Identification of a conserved interface of HIV-1 and FIV Vifs with Cullin 5. J Virol. 2017;: pubmed publisher
    ..While our structural model suggests that the diverse FIV and HIV-1 Vifs use conserved residues for Cullin 5 binding, FIV Vif binds Cullin 5 independently of zinc in contrast to HIV-1 Vif. ..

Detail Information

Publications7

  1. M nk C, Willemsen A, Bravo I. An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol Biol. 2012;12:71 pubmed publisher
    ....
  2. Munk C, Jensen B, Zielonka J, Haussinger D, Kamp C. Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein. Viruses. 2012;4:3132-61 pubmed publisher
    ..Both experimental evidence and the substantiation of the underlying dynamics through coevolutionary models are presented as complementary views of a coevolutionary arms race. ..
  3. Bähr A, Singer A, Hain A, Vasudevan A, Schilling M, Reh J, et al. Interferon but not MxB inhibits foamy retroviruses. Virology. 2016;488:51-60 pubmed publisher
    ..IFN-β treated THP-1 and THP-1 KO MxB cells showed the same extend of restriction to FV. Together, the data demonstrate that IFN-β inhibits FV early in infection and that MxB is not a restriction factor of FV. ..
  4. Zhang Z, Gu Q, Jaguva Vasudevan A, Hain A, Kloke B, Hasheminasab S, et al. Determinants of FIV and HIV Vif sensitivity of feline APOBEC3 restriction factors. Retrovirology. 2016;13:46 pubmed publisher
    ..Only A3Z3 and A3Z2Z3 inhibit Vif-deficient FIV. Feline A3s also are restriction factors for HIV and Simian immunodeficiency viruses (SIV). Surprisingly, HIV-2/SIV Vifs can counteract feline A3Z2Z3...
  5. Jaguva Vasudevan A, Hofmann H, Willbold D, Haussinger D, Koenig B, Munk C. Enhancing the Catalytic Deamination Activity of APOBEC3C Is Insufficient to Inhibit Vif-Deficient HIV-1. J Mol Biol. 2017;429:1171-1191 pubmed publisher
    ..We conclude that the enhanced enzymatic activity of A3C is insufficient to restrict HIV-1, indicating an unknown escape mechanism of HIV-1. ..
  6. Jaguva Vasudevan A, Goering W, Haussinger D, Munk C. Detection of APOBEC3 Proteins and Catalytic Activity in Urothelial Carcinoma. Methods Mol Biol. 2018;1655:97-107 pubmed publisher
    ..Here we combine independent immunoblotting with an in vitro activity assay technique, to detect and categorize specific A3s expressed in urothelial bladder cancer and other cancer cells. ..
  7. Gu Q, Zhang Z, Gertzen C, Haussinger D, Gohlke H, Munk C. Identification of a conserved interface of HIV-1 and FIV Vifs with Cullin 5. J Virol. 2017;: pubmed publisher
    ..While our structural model suggests that the diverse FIV and HIV-1 Vifs use conserved residues for Cullin 5 binding, FIV Vif binds Cullin 5 independently of zinc in contrast to HIV-1 Vif. ..